Related references
Note: Only part of the references are listed.Fingolimod Provides Long-Term Protection in Rodent Models of Cerebral Ischemia
Ying Wei et al.
ANNALS OF NEUROLOGY (2011)
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY (2010)
The changing demographic pattern of multiple sclerosis epidemiology
Nils Koch-Henriksen et al.
LANCET NEUROLOGY (2010)
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
G. Comi et al.
MULTIPLE SCLEROSIS (2010)
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
M. Mehling et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
Volker Brinkmann
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro
P. J. Zhou et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
The Sphingosine 1-Phosphate Receptor Agonist FTY720 Potently Inhibits Regulatory T Cell Proliferation In Vitro and In Vivo
Anna Maria Wolf et al.
JOURNAL OF IMMUNOLOGY (2009)
Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy
Hye-Jung Kim et al.
JOURNAL OF NEUROIMMUNOLOGY (2009)
Oral fingolimod (FTY720) in multiple sclerosis Two-year results of a phase II extension study
P. O'Connor et al.
NEUROLOGY (2009)
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2008)
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis
[Anonymous]
ARCHIVES OF NEUROLOGY (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
"Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets
K. Takabe et al.
PHARMACOLOGICAL REVIEWS (2008)
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis
Chitra Krishnan et al.
ARCHIVES OF NEUROLOGY (2008)
Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
Volker Brinkmann
PHARMACOLOGY & THERAPEUTICS (2007)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis -: reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
Florian Then Bergh et al.
BMC NEUROLOGY (2006)
The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity
E Sawicka et al.
JOURNAL OF IMMUNOLOGY (2005)
Essential role for sphingosine kinases in neural and vascular development
K Mizugishi et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice
M Webb et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation
ML Allende et al.
BLOOD (2003)
Amelioration of experimental autoimmune encephalomyelitis in lewis rats by FTY720 treatment
M Fujino et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
V Brinkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator?
F Okajima
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2002)
Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors
S Siehler et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2002)
Share Paper
